Skip to content

Sana Biotechnology SANA Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$12.89M
CG Oncology logo
CG OncologyCGON
$47K-79.7%
Vor Biopharma logo
Vor BiopharmaVOR
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$907.23M+54.1%
Enterprise value$898.76M+53.9%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Reported directly by Sana Biotechnology in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sana Biotechnology's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sana Biotechnology's payments of stock issuance costs?
Sana Biotechnology (SANA) reported payments of stock issuance costs of $96K in Q1 2026.